Rafferty Asset Management, LLC Tcr2 Therapeutics Inc. Transaction History

Rafferty Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$4.58 - $8.34 $248,510 - $452,528	-54,260 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$8.44 - $18.35 $358,067 - $778,498	-42,425 Reduced 43.88%	54,260 $462,000
Q2 2021 Aug 10, 2021	SELL	$16.41 - $24.71 $307,342 - $462,793	-18,729 Reduced 16.23%	96,685 $1.59 Million
Q1 2021 May 10, 2021	BUY	$20.38 - $34.07 $2.2 Million - $3.67 Million	107,759 Added 1407.69%	115,414 $2.55 Million
Q4 2020 Feb 10, 2021	BUY	$19.0 - $32.63 $145,445 - $249,782	7,655 New	7,655 $237,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.